Cardiotoxicity of BRAF/MEK Inhibitors: A Longitudinal Study Incorporating Contemporary Definitions and Risk Scores

BACKGROUND: Rapidly accelerated fibrosarcoma B-type (BRAF) and mitogen-activated extracellular signal-regulated kinase (MEK) inhibitors have revolutionized treatment for patients with BRAF-mutated melanoma. Although left ventricular systolic dysfunction associated with these therapies has been repor...

Descripción completa

Detalles Bibliográficos
Autores principales: Glen, Claire, Adam, Sarah, McDowell, Kirsty, Waterston, Ashita, Tan, Yun Yi, Petrie, Mark C., Coats, Caroline J., Lang, Ninian N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635885/
https://www.ncbi.nlm.nih.gov/pubmed/37969652
http://dx.doi.org/10.1016/j.jaccao.2023.04.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635885/
https://www.ncbi.nlm.nih.gov/pubmed/37969652
http://dx.doi.org/10.1016/j.jaccao.2023.04.004

Ejemplares similares